Search   
MSDS  : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl) thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino )-, (6R-trans)-, sodium salt
CAS  : 27164-46-1
SYNONYMS  : * Ancef * Biazolina * Cefamedin * Cefazoline sodium * Cefazolin sodium salt * CEZ sodium * Firmacef * Gramaxin * Kefzol * Lampocef * Liviclina * Monosodium cefazolin * SKF 41558 * Sodium cefazolin * Sodium cephazolin * Sodium CEZ * Totacef * Zolicef
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : XI0390000
CHEMICAL NAME : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic
acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)
thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino
)-, (6R-trans)-, sodium salt
CAS REGISTRY NUMBER : 27164-46-1
LAST UPDATED : 199706
DATA ITEMS CITED : 28
MOLECULAR FORMULA : C14-H13-N8-O4-S3.Na
MOLECULAR WEIGHT : 476.52
WISWESSER LINE NOTATION : T46 ANV ES GUTJ HVO CMV1- AT5NNNNJ& G1S- CT5NN DSJ E1
&-NA-
COMPOUND DESCRIPTOR : Drug
Reproductive Effector
Human
SYNONYMS/TRADE NAMES :
* Ancef
* Biazolina
* Cefamedin
* Cefazoline sodium
* Cefazolin sodium salt
* CEZ sodium
* Firmacef
* Gramaxin
* Kefzol
* Lampocef
* Liviclina
* Monosodium cefazolin
* SKF 41558
* Sodium cefazolin
* Sodium cephazolin
* Sodium CEZ
* Totacef
* Zolicef

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Human - woman
DOSE/DURATION : 660 mg/kg/11D-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
NPRNAY Nephron. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003)
V.1- 1964- Volume(issue)/page/year: 45,72,1987

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Human
DOSE/DURATION : 14 mg/kg/D
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands
Gastrointestinal - nausea or vomiting
Skin and Appendages - dermatitis, allergic (after systemic exposure)
REFERENCE :
JMGZAI Japan Medical Gazette. (Tokyo, Japan) V.1-18(?), 1964-81.
Discontinued. Volume(issue)/page/year: 8(8),10,1971

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : >11 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 7400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,404,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 10 gm/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - convulsions or effect on seizure threshold
Gastrointestinal - hypermotility, diarrhea
REFERENCE :
JMGZAI Japan Medical Gazette. (Tokyo, Japan) V.1-18(?), 1964-81.
Discontinued. Volume(issue)/page/year: 8(8),10,1971

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 2760 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
Behavioral - ataxia
Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
35(Suppl 1),207,1987

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : >11 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 6200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,404,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 7600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JIDIAQ Journal of Infectious Diseases. (Univ. of Chicago Press, Journals
Div., POB 37005, Chicago, IL 60637) V.1- 1904- Volume(issue)/page/year:
128,S379,1973

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 3900 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JIDIAQ Journal of Infectious Diseases. (Univ. of Chicago Press, Journals
Div., POB 37005, Chicago, IL 60637) V.1- 1904- Volume(issue)/page/year:
128,S379,1973

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 4 gm/kg
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands
Gastrointestinal - hypermotility, diarrhea
Gastrointestinal - nausea or vomiting
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 2200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 29,424,1979

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : >6 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : 2500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 29,424,1979

** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 112 gm/kg/28D-I
TOXIC EFFECTS :
Blood - normocytic anemia
Blood - changes in bone marrow (not otherwise specified)
Related to Chronic Data - changes in prostate weight
REFERENCE :
JZKEDZ Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental
Animals, Research Reports. (Jikken Dobutsu Chuo Kenkyusho, 1433 Nogawa,
Takatsu-ku, Kawasaki 211, Japan) V.1- 1975- Volume(issue)/page/year:
2,1,1976

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 91 gm/kg/13W-I
TOXIC EFFECTS :
Endocrine - changes in spleen weight
Blood - changes in spleen
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 21 gm/kg/21D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure,
acute tubular necrosis)
Kidney, Ureter, Bladder - other changes in urine composition
Nutritional and Gross Metabolic - changes in chlorine
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
40(Suppl 4),162,1992

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 42875 mg/kg/5W-I
TOXIC EFFECTS :
Gastrointestinal - other changes
Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda
Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960-
Volume(issue)/page/year: 18,1793,1984

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 91 gm/kg/13W-I
TOXIC EFFECTS :
Blood - normocytic anemia
Blood - changes in spleen
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 45500 mg/kg/26W-I
TOXIC EFFECTS :
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 72 gm/kg/13W-I
TOXIC EFFECTS :
Liver - changes in liver weight
Blood - normocytic anemia
Biochemical - Enzyme inhibition, induction, or change in blood or tissue
levels - transaminases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
35(Suppl 1),251,1987

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 7500 mg/kg/30D-I
TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting
Liver - fatty liver degeneration
Kidney, Ureter, Bladder - other changes
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
18,528,1970

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : 2800 mg/kg/7D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
Biochemical - Enzyme inhibition, induction, or change in blood or tissue
levels - transaminases
Related to Chronic Data - death
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
27(Suppl 5),701,1979

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE : 5500 mg/kg
SEX/DURATION : female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
resorbed implants per total number of implants)
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured
before birth)
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures
(e.g., placenta, umbilical cord)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
28(Suppl 7),1119,1980

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE : 5500 mg/kg
SEX/DURATION : female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
gain)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
28(Suppl 7),1119,1980

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE : 21 gm/kg
SEX/DURATION : female 17-22 day(s) after conception
lactating female 20 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
Reproductive - Maternal Effects - uterus, cervix, vagina
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
gain)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
35(Suppl 1),404,1987

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE : 21 gm/kg
SEX/DURATION : female 17-22 day(s) after conception
lactating female 20 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki,
Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year:
35(Suppl 1),404,1987

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - X3195
No. of Facilities: 675 (estimated)
No. of Industries: 1
No. of Occupations: 6
No. of Employees: 27888 (estimated)
No. of Female Employees: 22194 (estimated)


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
5-Thia-1-azabicyclo(4,2,0)oct-2-ene-2-carboxylicacid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester), monosodiumsalt 24356-60-3
2-Thenylamine, N,N-bis(2-chloroethyl)-5-methyl- 3331-95-1
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester) 153-61-7
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate, monosodium salt 58-71-9
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, sodium salt 5547-29-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((((4-hydroxy-6-methyl-3-pyridinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-t etrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt,(6R-(6-alpha,7-beta(R*)))- 74849-93-7
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-,(6R-(6-alpha,7-beta(R*)))- 34444-01-4
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-sulfomethyl)-1H-tetrazol-5-yl) thio)methyl)-,(6R-(6-alpha,7-beta(R*)))- 61270-58-4
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((((5-hydroxy-2-(1-piperazinyl)pyrido(2,3-d)pyrimidin-6-yl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)- 3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt,(6R-(6-alpha,7-beta(R*)))- 60837-22-1
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-((((1-imino-2-phenylethyl)amino)acetyl)amino)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-, (6R-trans)- 40158-24-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodiumsalt, D- 30034-03-8
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(4-methoxyphenyl)cyclopentyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-26-6
2-Thenylamine, N,N-bis(2-chloroethyl)-5-methyl-,hydrochloride 14742-54-2
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(3-methoxyphenyl)cyclopropyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-17-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(4-methoxyphenyl)cyclopropyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-18-6
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-methyl-8-oxo-7-(((1-phenylcyclopentyl)carbonyl)amino)-,(6R-trans)- 108098-25-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-methyl-8-oxo-7-(((1-phenylcyclopropyl)carbonyl)amino)-,(6R-trans)- 108098-16-4
5-Thia-1-azabicyclo(4,2,0)oct-2-ene-2-carboxylicacid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-(6R,7R)-7-(2-(3,5-dichloro-4-oxo-1(4H)-pyridyl)acetamid o)-, monosodium salt 63521-15-3
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)- 25953-19-9
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-, mixed with sodium nitrite (1:4) 25953-19-9
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino)-, (6R-trans)-, sodium salt 27164-46-1
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 8-oxo-7-((1H-tetrazol-1-ylacetyl)amino)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-,monosodium salt, (6R-trans)- 41136-22-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(4-propoxyphenyl)cyclobutyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-22-2
Tetrodotoxin, O(sup 4)-methyl- 7724-39-2
2-Thenylamine, alpha-(p-bromobenzyl)-, hydrochloride 80154-75-2
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(2-propoxyphenyl)cyclopentyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-30-2
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(3-propoxyphenyl)cyclopentyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-29-9
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(4-propoxyphenyl)cyclopentyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-28-8
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(2-propoxyphenyl)cyclopropyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108098-20-0
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid, 7-(((1-(4-propoxyphenyl)cyclopropyl)carbonyl)amino)-3-methyl-8-oxo-, (6R-trans)- 108146-11-8
1-Thia-3-aza-2-silacyclopentane,2-(p-chlorophenyl)-2,5-diphenyl- 102367-62-4
1-Thia-3-aza-2-silacyclopentane,2-(p-chlorophenyl)-2-methyl- 84260-43-5
1-Thia-3-aza-2-silacyclopentane, 2,2-diethyl- 84260-21-9
1-Thia-3-aza-2-silacyclopentane,2,2-diethyl-5-methyl- 84260-33-3
1-Thia-3-aza-2-silacylcopentane, 2,2-dimethyl- 84260-28-6
2-Thenylamine, alpha-(p-bromobenzyl)-N-isopropyl-,hydrochloride 80154-76-3
1-Thia-3-aza-2-silacyclopentane,2,5-dimethyl-2-(p-fluorophenyl)- 84260-41-3
1-Thia-3-aza-2-silacyclopentane,2,5-dimethyl-2-(p-methoxyphenyl)- 84260-39-9
1-Thia-3-aza-2-silacyclopentane,2,5-dimethyl-2-phenyl- 84260-31-1
1-Thia-3-aza-2-silacyclopentane, 2,2-diphenyl- 84260-35-5
1-Thia-3-aza-2-silacyclopentane,2-(p-fluorophenyl)-2-methyl- 84260-27-5
1-Thia-3-aza-2-silacyclopentane,2-(p-methoxyphenyl)-2-methyl- 84260-25-3
1-Thia-3-aza-2-silacyclopentane, 2-methyl-2-phenyl- 84260-23-1
1-Thia-3-aza-2-silacyclopentane,2-methyl-2-(p-tolyl)- 84260-37-7
1-Thia-4-azaspiro(4.5)decane, 8-methyl-,hydrochloride 31404-04-3
2-Thia-7-azaspiro(4.4)nonane-6,8-dione, 7-allyl- 10288-31-0
3-Thenylamine, 2-bromo-N,N-bis(2-chloroethyl)-,hydrochloride 13792-99-9
7-Thiabicyclo(2.2.1)heptane-2,3-dicarboxylic acid,(exo,exo)- 109282-39-5
9-Thiabicyclo(3.3.1)nonane, 2,6-dichloro- 6522-21-0
8-Thia-1,3-diazaspiro(4.5)decane-2,4-dione 39124-15-7

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net